Clinical Questions in Cardiology: Using Glucagon-like Peptide-1 Receptor Agonists
Released On
January 31, 2024
Expires On
February 28, 2025
Media Type
Internet
Completion Time
75 Minutes
Specialty
Cardiology, Endocrinology, Gastroenterology, Primary Care
Topic(s)
Cardiovascular Disease, Diabetes
Sponsored by the Annenberg Center for Health Sciences.
This activity is supported by an independent educational grant from Novo Nordisk.
Credit Available
- Physicians — maximum of 1.25 AMA PRA Category 1 Credits™
- Physician Associates — maximum of 1.25 AMA AAPA Category 1 Credits™
- Nurses — 1.25 American Nurses Credentialing Center (ANCC) Contact Hour
- CA-BRB - 1.25 contact hours, Provider #13664
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The target audience includes cardiologists and cardiology advanced practice providers who treat patients with type 2 diabetes (T2D), and other clinicians with an interest in T2D.
Program Overview
The glucagon-like peptide-1 receptor agonist (GLP-1RA) class of medications has become an important option for treating patients with type 2 diabetes mellitus (T2D). Cardiovascular outcome trials also show that selected GLP-1RAs exert beneficial cardiovascular benefits in patients with and without T2D. In this activity, case studies commonly encountered in cardiology practice are utilized to prompt reflection on opportunities for reducing cardiovascular risk. Drawing on seminal research and their own experience, cardiologist Jorge Plutzy, MD, and endocrinologist Helena Rodbard, MD, navigate through a series of ‘clinical questions’ to inform regarding the clinical pharmacology of the GLP-1RAs and their evidence-based role in cardiovascular risk reduction, particularly in patients with secondary atherosclerotic cardiovascular disease. The faculty also provide recommendations to optimize the use of GLP-1RAs as a class, as well as individually, including strategies to mitigate gastrointestinal adverse events and address patient concerns. In closing, Dr. Plutzky underscores the essential role of cardiologists in diabetes care, advocating for a collaborative, interprofessional team approach to optimize the health of patients with chronic coronary disease.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Explain how the mechanisms of action of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) address key pathophysiologic mechanisms of type 2 diabetes
- Compare and contrast the agents within the GLP-1RA class
- Formulate strategies to ease patient safety concerns and improve tolerability to GLP-1 RAs
- Justify the use of GLP-1 RAs for secondary prevention of cardiovascular disease in patients with type 2 diabetes
- Apply current evidence-based recommendations from the ACC, ADA, and ADA/EASD to individualize GLP-1RA therapy in patients with type 2 diabetes
Faculty
Jorge Plutzky, MD
Director, Preventive Cardiology
Cardiovascular Medicine
Brigham and Women's Hospital
Boston, Massachusetts
Helena W. Rodbard, MD
Past President, American Association of Clinical Endocrinologists (AACE)
Past President, American College of Endocrinology (ACE)
Founder and Medical Director, Endocrine and Metabolic Consultants
Rockville, Maryland
Accreditation Statement
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit
The Annenberg Center designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Associate Credit
The Annenberg Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Nurse Credit
The Annenberg Center designates this education for a maximum of 1.25 American Nurses Credentialing Center (ANCC) contact hours, including 1.0 pharmacology hour.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.25 contact hours. To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Disclosures of Conflicts of Interest
- Helena W. Rodbard, MD
- Consultant: Pacira
- Research Support: Eli Lilly, Inversago, Medtronic, Novo Nordisk, Sanofi
- Speakers Bureau: Bayer, Boehringer Ingelheim, Merck
The following have no significant relationship to disclose:
Jorge Plutzky, MD
The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Additional content planners
The following have no significant relationship to disclose:
Chandler D. Schexnayder, PharmD (Medical Writer)
Eugene Cullen, MD (Peer Reviewer)
Annenberg Center for Health Sciences:
All staff at the Annenberg Center have no relevant financial relationships to disclose.
All the relevant financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.
Disclaimer
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center for Health Sciences at Eisenhower disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information
For CME questions please contact: [email protected].